The African Community Advisory Board (AfroCAB) released a statement on dolutegravir (DTG) and neural tube defects in women living with HIV (WLHIV) of child bearing age.
“Since information has been shared from a cohort of women living with HIV in Botswana indicating a potential link between neural tube defects and dolutegravir (DTG) use at the time of conception, many statements have been released by various stakeholders. Some of the statements have been helpful, others alarmist and misleading. But they all have one thread in common: no community consultation.”
Download the full statement here: